Price
$145.2
Increased by +0.25%
Dollar Volume
924.08 M
ADR%
1.89
Earnings Report Date (estimate)
Feb 9, 23 (3.57)
Market Cap.
256.78 B
Shares Float
1.77 B
Shares Outstanding
1.77 B
Beta
0.62
Price / Earnings
19.36
BPR
62.12
20D Range
143.44 166.53
50D Range
143.44 166.53
200D Range
131.49 166.53
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Oct 28, 22 3.66
Increased by +9.91%
3.57
Increased by +2.52%
Jul 29, 22 3.37
Increased by +8.36%
3.31
Increased by +1.81%
Apr 29, 22 3.16
Increased by +7.12%
3.14
Increased by +0.64%
Feb 2, 22 3.31
Increased by +13.36%
3.29
Increased by +0.61%
Oct 29, 21 3.33
Increased by +17.67%
3.22
Increased by +3.42%
Jul 30, 21 3.11
Increased by +32.91%
3.09
Increased by +0.65%
Apr 30, 21 2.95
Increased by +21.90%
2.83
Increased by +4.24%
Feb 3, 21 2.92
Increased by +32.13%
2.85
Increased by +2.46%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 14.81 B
Increased by +3.28%
3.95 B
Increased by +24.22%
Increased by +26.66%
Increased by +20.28%
Jun 30, 22 14.58 B
Increased by +4.47%
924.00 M
Increased by +20.63%
Increased by +6.34%
Increased by +15.47%
Mar 31, 22 13.54 B
Increased by +4.06%
4.49 B
Increased by +26.37%
Increased by +33.17%
Increased by +21.44%
Dec 31, 21 14.89 B
Increased by +7.42%
4.04 B
Increased by +11.13 K%
Increased by +27.17%
Increased by +10.36 K%
Sep 30, 21 14.34 B
Increased by +11.16%
3.18 B
Increased by +37.74%
Increased by +22.17%
Increased by +23.91%
Jun 30, 21 13.96 B
Increased by +33.90%
766.00 M
Increased by +203.79%
Increased by +5.49%
Increased by +177.52%
Mar 31, 21 13.01 B
Increased by +50.95%
3.55 B
Increased by +18.04%
Increased by +27.31%
Decreased by -21.80%
Dec 31, 20 13.86 B
Increased by +59.21%
36.00 M
Decreased by -98.71%
Increased by +0.26%
Decreased by -99.19%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.